Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.

[1]  Luhua Lai,et al.  Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase. , 2011, Journal of medicinal chemistry.

[2]  B. Roth,et al.  The expanded biology of serotonin. , 2009, Annual review of medicine.

[3]  Luhua Lai,et al.  Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.

[4]  O. Werz,et al.  Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. , 2008, Journal of medicinal chemistry.

[5]  L. Lai,et al.  Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.

[6]  O. Werz,et al.  Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. , 2008, Journal of medicinal chemistry.

[7]  J. Haeggström,et al.  Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. , 2008, Bioorganic & medicinal chemistry.

[8]  István A. Kovács,et al.  How to design multi-target drugs , 2007, Expert opinion on drug discovery.

[9]  Edward A Dennis,et al.  The phospholipase A2 superfamily and its group numbering system. , 2006, Biochimica et biophysica acta.

[10]  L. Lai,et al.  A continuous fluorescence assay for phospholipase A2 with nontagged lipid. , 2006, Analytical biochemistry.

[11]  Mark C. Fishman,et al.  Pharmaceuticals: A new grammar for drug discovery , 2005, Nature.

[12]  G. Moore,et al.  2,6-Di-tert-butyl-4-(2′-thenoyl)phenol(R-830): A novel nonsteroidal anti-inflammatory agent with antioxidant properties , 1982, Agents and Actions.

[13]  K. Rainsford.  Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage , 2005, Agents and Actions.

[14]  J. Haeggström.  Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis* , 2004, Journal of Biological Chemistry.

[15]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[16]  S. Lipton.  Turning down, but not off , 2004, Nature.

[17]  E. Werner.  Systems biology: the new darling of drug discovery? , 2002, Drug discovery today.

[18]  Valérie Choesmel,et al.  Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[19]  E. Dennis,et al.  The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. , 2000, Biochimica et biophysica acta.

[20]  H. Breitinger,et al.  Synthesis and characterization of photolabile derivatives of serotonin for chemical kinetic investigations of the serotonin 5-HT(3) receptor. , 2000, Biochemistry.

[21]  J. Gierse,et al.  Structure−Activity Relationship Studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A4 (LTA4) Hydrolase , 2000 .

[22]  J. Haeggström,et al.  Structure, function, and regulation of leukotriene A4 hydrolase. , 2000, American journal of respiratory and critical care medicine.

[23]  M. Rogawski,et al.  Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents – toward an understanding of their favorable tolerability , 2000, Amino Acids.

[24]  J. L. Raszkiewicz,et al.  NPS 1506, A Novel NMDA Receptor Antagonist and Neuroprotectant: Review of Preclinical and Clinical Studies , 1999, Annals of the New York Academy of Sciences.

[25]  D. McCarthy,et al.  The Low‐Affinity, Use‐Dependent NMDA Receptor Antagonist AR‐R 15896AR: An Update of Progress in Stroke , 1999, Annals of the New York Academy of Sciences.

[26]  D. R. Berry,et al.  Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. , 1996, Journal of medicinal chemistry.

[27]  John Steele,et al.  Thromboxane modulating agents. 1. Design of 1-[(arylsulfonyl)amino] alkylindole derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists. , 1995 .

[28]  I. Ollmann,et al.  Investigation of the inhibition of leukotriene A4 hydrolase. , 1995, Bioorganic & medicinal chemistry.

[29]  J.-P. Wery,et al.  Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.

[30]  T. Inoue,et al.  Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives. , 1994, Journal of medicinal chemistry.

[31]  S. Laufer,et al.  (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. , 1994, Journal of medicinal chemistry.

[32]  R. D. Dyer,et al.  Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. , 1994, Journal of medicinal chemistry.

[33]  M. Moskowitz,et al.  Further characterization of the putative 5‐HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater , 1991, British journal of pharmacology.

[34]  S. Peroutka,et al.  5-benzyloxytryptamine: a relatively selective 5-hydroxytryptamine 1D/1B agent. , 1991, Life sciences.